MDACC Study No:CERN08-01 ( NCT No: NCT00883688)
Title:A Phase II Study of Bevacizumab and Lapatinib in Children with Recurrent or Refractory Ependymoma
Principal Investigator:Michael E. Rytting
Treatment Agent:Bevacizumab; Lapatinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the combination of
Avastin (bevacizumab) and Tykerb (lapatinib) can help to control ependymoma in
pediatric patients. The safety of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Brain; Pediatrics
Phase of Study:Phase II
Treatment Agents:Bevacizumab
Treatment Location:Both at MDACC & Community Programs (CCOP/Network)
Estimated Length of Stay in Houston:No hospitalization is required unless it become clinically necessary.
Supported By:Collaborative Ependymoma Research Network
Return Visit:Once a week for 1 month, then twice a month for a 2 years for an estimated
total of 52 visits.
Home Care:Lapatinib is given orally and may be given at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael E. Rytting
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults